Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1Classical hematology 1

Conditions

Pancreatic Neoplasms 8Unspecified Adult Solid Tumor, Protocol Specific 1Resectable Pancreatic Carcinoma 1Resectable Pancreatic Cancer 1Rectal Neoplasms 1Prostatic Neoplasms 1Pancreatic Ductal Adenocarcinoma 1Neoplasms, Plasma Cell 1Neoplasm Metastasis 1Myelodysplastic Syndromes 1Multiple Myeloma 1Leukemia, Myelomonocytic, Chronic 1Leukemia 1Breast Neoplasms 1Anemia, Refractory, with Excess of Blasts 1Anemia, Refractory 1Advanced Pancreatic Cancer 1Adenocarcinoma of the Pancreas 1Adenocarcinoma 1

Interventions

fludarabine phosphate 60Cyclophosphamide 60Busulfan 43Cyclosporine 41Mycophenolic Acid 40Peripheral Blood Stem Cell Transplantation 39Cytarabine 36Whole-Body Irradiation 34Antilymphocyte Serum 29Filgrastim 26Tacrolimus 24Methotrexate 24fludarabine 23Cord Blood Stem Cell Transplantation 22Radiotherapy 21Melphalan 20Etoposide 18Methylprednisolone 15Azacitidine 14Granulocyte Colony-Stimulating Factor 13Idarubicin 12Daunorubicin 11Thiotepa 10sargramostim 8Cyclosporins 8Clofarabine 7Arsenic Trioxide 7Transplantation 6Topotecan 6Mitoxantrone 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Anemia, Refractory, with Excess of Blasts × paricalcitol × Clear all
NCT00064376 2018-01-29

Paricalcitol in Treating Patients With Myelodysplastic Syndrome

Cedars-Sinai Medical Center

Phase 2 Completed
Classical hematologyMyeloidOther hematologic neoplasm

Anemia, Refractory, Anemia, Refractory, with Excess of Blasts, Leukemia, Myelodysplastic Syndromes, Leukemia, Myelomonocytic, Chronic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡